32 results on '"Morere J."'
Search Results
2. Assessment of pathologic response to neoadjuvant chemotherapy in locally advanced non-small cell lung cancer using FDG-PET/CT: SUVmax versus metabolic tumor volume.
3. Meta-analysis of efficacy and safety of single-agent and doublet chemotherapy with or without platinum in advanced non-small cell lung cancer in the elderly.
4. Prognostic impact of microsatellite instability in colorectal cancer patients treated with adjuvant FOLFOX.
5. Mammography utilization in women age 40 to 49: The French EDIFICE survey.
6. Comparison of efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: A meta-analysis.
7. Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis.
8. Trends in screening for prostate cancer
9. Prevalence of renal insufficiency in cancer patients: Data from the IRMA-2 study
10. Does microsatellite instability predict the effect of adjuvant chemotherapy in stage III colorectal cancer? A meta-analysis
11. Impact of renal insufficiency on cancer survival: Results of the IRMA-2 study
12. Renal function evolution in cancer patients. Results of the IRMA-2 study
13. Microsatellite instability as a predictor of chemotherapy efficacy in colorectal cancer
14. Frequency and current management of erlotinib-related skin effects
15. IFCT0401-bio phase II trial: Gefitinib administered as 1st-line in non-resectable adenocarcinoma with bronchioloalveolar carcinoma features (ADC-BAC)—Predictive biomarkers of efficacy and survival
16. Randomized phase II trial of first-line gefitinib, gemcitabine or docetaxel in performance status (PS) 2 or 3 non-small-cell lung cancer (NSCLC) patients (IFCT-0301)
17. Investigation on the advantage of interdisciplinary boards for patients receiving palliative treatment in a medical oncology department
18. Anemia, renal disease, and chemotherapy in the IRMA study
19. Role of MSI and DCC status to predict response to FOLFOX in metastatic colorectal cancer
20. Mechanism of bevacizumab-induced arterial hypertension: Relation with skin capillary rarefaction in patients treated for metastatic colorectal cancer
21. A randomized phase II study of concomitant CT (docetaxel±cisplatin) and (RT) in first-line treatment of locally advanced head and neck cancer (LAHNC)
22. IFCT0401-bio trial: Predictive biological markers for disease control (DC) of patients with non-resectable, adenocarcinoma with bronchioloalveolar carcinoma features (ADC-BAC) treated with gefitinib
23. Renal insufficiency in bone metastasis cancer patients: Prevalence and implications on anticancer drugs management, subgroup analysis of the IRMA study
24. Results of a prospective study with FOLFOX and Ca/Mg infusions for treatment of advanced and metastatic gastric carcinoma
25. Impact of organization of colorectal cancer screening: Results of EDIFICE study
26. Cancer screening tests in France: First results of EDIFICE study
27. Effect of paclitaxel-carboplatin (PC) consolidation chemotherapy after weekly PC concurrent chemo-radiotherapy (CCR) for patients with locally advanced non-small cell lung cancer (LA-NSCLC): 3-year definitive results of the B001-phase III GERCOR-study
28. Renal insufficiency in cancer patients: Prevalence and implications on anticancer drugs management. Results of the IRMA study
29. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature
30. Retrospective study of compassionnal treatment of gefitinib 250 mg/d in non small cell lung cancer (NSCLC). The Hopital Avicenne experience
31. EGFR and phospho-EGFR expression in colorectal cancer patients and impact on survival
32. A new docetaxel (D) gemcitabine (G) regimen as first-line chemotherapy in advanced non-small cell lung cancer (NSCLC): A phase II study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.